Praxis Precision Medicines, Inc. PRAX Cash Cash Equivalents And Short Term Investments

Cash Cash Equivalents And Short Term Investments at other companies

Jazz PharmaceuticalsJAZZ

——

Rhythm Pharmaceuticals, Inc.RYTM

——

Krystal Biotech, Inc.KRYS

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$105.9M-41.7%

Net income-$92.6M-33.6%

EPS (diluted)-$3.20+2.7%

Balance sheet

See full

Cash & equivalents$536.7M+223%

Total debt$1.4M+31.3%

Total equity$1.4B+221%

Total assets$1.5B+205%

Cash flow

See full

Operating cash flow-$86.2M-62.5%

CapEx$62.0K—

Free cash flow-$86.2M-62.6%

Valuation

See full

Market cap$7.87B+1,075%

Enterprise value$7.34B+1,309%

Profitability

See full

Operating margin-3,927.5%-1,497pp

Net margin-3,658.5%-1,388pp

FCF margin-3,067.4%-1,030pp

Returns & leverage

See full

Return on equity-35.3%-10.9pp

Debt / equity0×0.0×

Current ratio15.9×+7.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.

The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Praxis Precision Medicines, Inc.'s cash cash equivalents and short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Praxis Precision Medicines, Inc.'s cash cash equivalents and short term investments?: Praxis Precision Medicines, Inc. (PRAX) reported cash cash equivalents and short term investments of $1.4B in Q1 2026.
How has Praxis Precision Medicines, Inc.'s cash cash equivalents and short term investments changed year-over-year?: Praxis Precision Medicines, Inc.'s cash cash equivalents and short term investments increased by 196.6% year-over-year, from $472M to $1.4B.